Filippo Maria Capomacchia

Gynecologic Oncology at Candiolo Cancer Institute IRCCS

[IJGC @IJGConline]

Thrilled to welcome Dr. Filippo Capomacchia @FilippoCapom as our new #IJGC #EditorialFellow! He is a #GynOnc at the Candiolo Cancer Institute – IRCCS in Turin, Italy 🇮🇹

Welcome Filippo!!🤩

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @HelenaObermair @sofiabigardiGMD @marina_rosanu @ChakraRim @mcgouveia_

[IJGC @IJGConline]

Join us #IJGCclub
📆04/06/2025
⏰9am CST/4pm CET

Mark your calendars 📅 for an exciting #IJGCclub 💥

Modified radical hysterectomy for stage IB1 (≤2 cm) #cervicalcancer: assessment of temporal trends and oncologic outcomes in the US🇺🇸 with Jason Wright

💻 https://t.co/U879Rhb83X

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @HelenaObermair @sofiabigardiGMD @marina_rosanu @ChakraRim @FilippoCapom @mcgouveia_

[IJGC @IJGConline]

In this new episode of #IJGCConversations, Dr. Anna Fagotti @annafagottimd discusses #HIPEC in platinum-sensitive #ovariancancer #HORSETrial 🐎 @Unicatt

🎧 https://t.co/G2GL7bvZYM

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @HelenaObermair @sofiabigardiGMD @marina_rosanu @ChakraRim @FilippoCapom

[Filippo Maria Capomacchia @FilippoCapom]

Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: May bevacizumab add something? A large retrospective study

I’m proud to have contributed, congratulations to @ErgastiR and the whole team!

https://t.co/Vvql0sYAvk

[Nicolò Bizzarri @NicoloBizzarri]

Great opportunity to present your data in robotic surgery at @SERGS_org meeting in Italy!! Will be an amazing gathering of international experts in gyn robotics!! Looking forward 🤩 @ENYGO_official @years_network @ESGO_society @IGCSociety @IJGConline @IJGCfellows

[Filippo Maria Capomacchia @FilippoCapom]

Integrating clinical-molecular data to predict #PARPi efficacy in advanced #OvarianCancer after #ICS

✅ BRCA/HRD and CRS correlate with PFS
✅ CRS is a surrogate of PARPi efficacy
✅ Integrating BRCA/HRD, KELIM and CRS allows tailored maintenance

https://t.co/RhWoXfvpge

[Filippo Maria Capomacchia @FilippoCapom]

Check out our latest work on @ESMO_Open, exploring real-world outcomes of PARP inhibitors as maintenance therapy in advanced ovarian cancer.

@annafagottimd @clamarchetti81 @MatteoLoverro

https://t.co/sJ6xYj94Bp

[Nicolò Bizzarri @NicoloBizzarri]

The memory of our beloved Prof. Scambia lives everyday in our hearts as we do everything exactly how he taught us. We will make him proud of us while he is supervising us from the sky. Thank you to our Leader 🖤
@annafagottimd @frafanfani @ESGO_society @ESGEorg @ENYGO_official

[ESGO @ESGO_society]

The ESGO Council is extremely saddened to learn of the untimely death of Prof Giovanni Scambia, who was a great influence to and personal friend of many of our members. A moment of silence was held today during the Congress opening ceremony in his honour.

Prof Scambia touched the lives of countless patients, surgeons, fellows and others in the gynae oncology community.

We extend our condolences to his family and the many, many others who are mourning his passing. His memory will live on.